Mind Medicine Australia Webinar - Three

Webinar: Psychedelic-Assisted Psychotherapy For PTSD

Join this free, 60-minute online webinar to gain access to insights and learn about ground breaking treatments to chronic mental health conditions.

Dr Nigel Strauss (MBBS, DPM, FRANZCP) will discuss the nature, causes and presentations of PTSD and the treatments currently available.

He will describe:

- Why MDMA assisted psychotherapy may be helpful in the treatment of PTSD and the mechanism of its potential effectiveness
- How we will train therapists and what differentiates psychedelic psychotherapy from other types pf psychotherapy from a psychiatric point of view
- The history of MDMA assisted psychotherapy, research issues, potential problems, legal issues and what we might expect in the future

There will also be information about a newly created psychotherapy service and a professional network which psychotherapists and psychologists already working in this field are invited to join.

A link will be emailed to you with the viewing details once you have registered.

Following the presentation there will be a Q&A panel with Dr Nigel Strauss. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.

More about medicinal psychedelic treatments:

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.